The growing use of glucagon-like peptide-1 (GLP-1) receptor agonist medications to treat obesity has raised questions about their broader impact on prescription drug spending. A recent study by Prime Therapeutics (Prime) compared three-year, non-GLP-1 pharmacy spending between those who initiated GLP-1 therapy and matched controls, assessing whether use of GLP-1 medications changes pharmacy spending on other medications. This research addresses a critical evidence gap for payers by evaluating whether GLP-1 treatments may offset or increase overall pharmacy costs through changes in comorbidity and side effect management, informing future coverage and affordability decisions. 

Read the research poster